Salbutamol - Continuous Nebulised

**Medication**

- Salbutamol is a β₂ agonist
- In severe asthma it can be given as a continuous nebuliser

**Actions**

Salbutamol acts on β₂ adreno-receptors in the bronchial smooth muscle of the lungs to allow bronchodilation

**Indications**

Acute severe asthma not responding to initial treatment with intermittent inhaled salbutamol

**Adverse**

Although the incidence of all side effects is very low following intermittent inhalation, the continuous nebulised route commonly induces side effects, these may be so severe that the drug has to be discontinued

- Peripheral vasodilation with a reflex tachycardia
- Irritability, agitation, tremors, hyperactivity, headache
- Nausea and vomiting
- Hyperglycaemia
- Paradoxical bronchospasm
- Paradoxical hypoxaemia
- Hypokalaemia
Dosage

The dosage is the same regardless of the child’s age or weight, as the actual inhaled dose will be adjusted by the patient’s tidal volume.

Preparation

- Chart 100mg salbutamol in 50mL of 0.9% saline on the drug chart
- Using the 5mg in 2.5ml salbutamol nebules, draw up 20 nebules = 100mg in 50mL of solution
- Add this to 50mL of 0.9% saline
- This gives a final solution of 1mg/mL
- Deliver this volume to the nebuliser chamber via infusion pump

Administration

- Fill nebuliser bowl with 4mL of solution prior to commencing
- Run oxygen flow of 8L/min via the nebuliser
- Run infusion pump at 25mL/hour to deliver 25mg/hour
- Check the nebuliser regularly to ensure it is not over-filling

Special

- Ensure the patient is sitting upright
- The length of time of continuous nebulised salbutamol should be based on the clinical response. Discuss with a Senior Doctor.
- Consider the need for treatment escalation (to intravenous therapy) and plan for this
- Ensure appropriate monitoring – continuous oxygen saturations and cardiac monitoring
- The patient will often require 1:1 nursing care during this time
- Consider Paediatric Intensive Care review

Tags

accessory muscles, asthma, atomiser, bronchodilator, continuous, hypoxia, nebulised, nebuliser, salbutamol, steroids, ventolin, wheeze, wheezing

References


This document can be made available in alternative formats on request for a person with a disability.
<table>
<thead>
<tr>
<th>File Path:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Document Owner:</td>
<td>Dr Meredith Borland HoD, PMH Emergency Department</td>
</tr>
<tr>
<td>Reviewer / Team:</td>
<td>Kids Health WA Guidelines Team</td>
</tr>
<tr>
<td>Date First Issued:</td>
<td>4 September, 2013</td>
</tr>
<tr>
<td>Last Reviewed:</td>
<td>13 June, 2017</td>
</tr>
<tr>
<td>Approved by:</td>
<td>Dr Meredith Borland</td>
</tr>
<tr>
<td>Endorsed by:</td>
<td>Medical Advisory Committee</td>
</tr>
<tr>
<td>Standards Applicable:</td>
<td>NSQHS Standards: 🚪 🚪 🚪</td>
</tr>
</tbody>
</table>

**Printed or personally saved electronic copies of this document are considered uncontrolled**